Korean Market
EXCH
Kyongbo Pharmaceutical
★

Kyongbo Pharmaceutical Discloses 2025 Corporate Governance Report: Net Profit Plunges 96% and Lack of Dividend Predictability Highlights Shareholder Return Risks

 
EXCH
Kyongbo Pharmaceutical
★

Preliminary 1Q26 Results: Sales +9.1%, Operating Profit +489.3% YoY

 
PERI
Kyongbo Pharmaceutical
★

Kyongbo Pharma: Q1 2026 operating profit of 0.7B won but net loss; ADC investment and litigation risks highlighted

 
EXCH
Kyongbo Pharmaceutical
★

Correction of ADC Plant Investment: Amount Increased to KRW 96 Billion

 
EXCH
Kyongbo Pharmaceutical
★★★

2025 Net Income Plunges 97.7%, Operating Profit Down 66.3%